TRAUMAGEL Study Highlights Sustained Hemorrhage Control and Tourniquet Removal Without Rebleeding

Clinical cases demonstrate successful use of TRAUMAGEL during tourniquet conversion in prolonged field care, including in gunshot wounds, industrial trauma and sharp-force injuries NEW YORK (July 7, 2026) — Cresilon Inc. (“Cresilon”), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, today announced the publication of a peer-reviewed study evaluating the use of TRAUMAGEL® […] The post TRAUMAGEL Study Highlights Sustained Hemorrhage Control and Tourniquet Removal Without Rebleeding appeared first on Cresilon .